Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 29, 2014

MorphoSys, Temple's Moulder Center Make Antibody Therapeutics Deal

  • HuCAL developer MorphoSys has cut a discovery deal with the Moulder Center for Drug Discovery Research, allowing the Center access to the firm's Ylanthia® technology to validate new disease-related targets and produce therapeutic antibody candidates. Under the deal's terms, MorphoSys is getting an exclusive option to develop any antibodies that result from this alliance.

    The Moulder Center, where the Ylanthia library will be installed, is a unit of Temple University's School of Pharmacy that is described by Temple as a multidisciplinary research hub for further development of scientific discoveries identified by the university's faculty, scientists, and external partners into novel therapies. It features a Biotherapeutics Discovery Unit dedicated to drug design and lead optimization in disease areas including cancer and Alzheimer's disease.

    Temple says this deal will be a boon for its researchers. "Our new collaborative effort with MorphoSys will provide our faculty, staff, and students with the cutting-edge scientific tools necessary to identify the next generation of antibody therapeutics," said Magid Abou-Gharbia, Ph.D., associate dean for research in Temple's School of Pharmacy and director of the Moulder Center, in a statement. 

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »